HSTRF - Hollister Biosciences' Venom achieves $30M revenue milestone
Hollister Biosciences' (HSTRF) wholly-owned subsidiary Venom Extracts has achieved the first of two revenue milestones in accordance with definitive agreement terms, entered in connection with the acquisition of Venom.In the last week of September, Venom achieved the first revenue milestone by generating C$30M+ of revenue calculated from January 1, 2020.Thus, the company will issue 19.7M shares to certain former Venom shareholders at a deemed price of $0.20/Earn-Out share.
For further details see:
Hollister Biosciences' Venom achieves $30M revenue milestone